RLAY — Relay Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$18.49
+$0.11 (+0.60%)
Relay Therapeutics Inc (RLAY) is a biotechnology company listed on NASDAQ. It is led by Sanjiv K. Patel M.A., M.B.A., M.D., MBBS, based in 60 Hampshire Street, Cambridge, MA, United States, 02139, with about 193 employees. Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest reported RLAY revenue for 2025-09-30 was $0. Net income was -$74.1M. Revenue was down 100.0% from 2025-06-30 to 2025-09-30. RLAY currently screens at market cap $3.39B.
Use this RLAY page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RLAY quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RLAY SEC filings page. Lician reads the product cache first so this HTML stays unique to Relay Therapeutics Inc even when a live quote feed is slow.
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
RLAY Key Statistics
Market Cap
$3.39B
Volume
1.02M
Previous Close
$18.77
Day Range
$18.03 – $18.64
P/B Ratio
5.28
EPS
-$2.36
Revenue
$10.01M
Net Income
-$337.71M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-60.8%
Profit Margin
-3374.7%
Employees
193
RLAY Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $10.01M | $25.55M | $1.38M | $3.03M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$337.71M | -$341.97M | -$290.51M | -$363.87M |
| EPS (Diluted) | -$2.36 | -$2.79 | -$2.59 | -$3.82 |
Total Assets
$871.30M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$124.29M
Operating Cash Flow
-$249.11M
Free Cash Flow
$0.00
Relay Therapeutics Inc Company Information
- CEO, President & Director
- Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
- Headquarters
- 60 Hampshire Street, Cambridge, MA, United States, 02139
- Website
- www.relaytx.com
- Phone
- 617 370 8837
- IPO / Founded
- 2020-07-16
- Sector
- Healthcare
- Industry
- Biotechnology